ClearPoint Neuro Inc vs Trip.com Group Ltd — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while Trip.com Group Ltd trades at $45.91 (market cap $29.26B). The key difference: Trip.com Group Ltd is far larger — about 65.9× ClearPoint Neuro Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | TCOM | |
|---|---|---|
Market Cap | $444.14M | $29.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $78.96 |
52-Week Low | $8.66 | $39.84 |
Enterprise Value | $478.72M | $21.91B |
Dividend Yield | — | 0.42% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
TCOM trades at $46.14, down 0.22% on the day, with a neutral technical signal and bearish moving averages. The company reported strong 2025 revenue of $62.41B and net income of $33.29B, with high profitability margins. Recent news includes a $770M antitrust penalty in China, impacting sentiment, while Q2 2026 earnings are expected at $0.873 per share.
Outlook remains mixed: strong fundamentals and a consensus price target of $59.29 suggest upside, but regulatory risks and recent earnings misses pose challenges. The stock offers value with a low P/E of 6.88, yet investors must weigh growth sustainability against antitrust pressures and guidance concerns.
Trailing returns across standard periods
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →